Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04147338 · ClinicalTrials.gov registry record · Phase 1
A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 440
- Enrollment target
NCT04147338: Completed Phase 1 study, sponsored by Janssen Research & Development.
NCT04147338 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 440 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (633% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04147338, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 440 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the serum concentration of guselkumab after administration using three different devices in healthy participants.
Primary Outcome
Cmax is the maximum observed serum concentration.
Interventions
- DRUG Guselkumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2019-10-30 |
| Est. Completion | 2021-12-07 |
| Phase | Phase 1 |
What the finished NCT04147338 record still lists
NCT04147338 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (633% higher).
The record links to 0 conditions, and to 1 intervention - of which Guselkumab is the first listed.
NCT04147338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04147338 about?
NCT04147338 is a clinical study titled "A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants". The purpose of this study is to evaluate the serum concentration of guselkumab after administration using three different devices in healthy participants.
What is the current status of trial NCT04147338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 440 participants. The study started on 2019-10-30. Estimated completion is 2021-12-07.
What interventions are being tested in trial NCT04147338?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT04147338?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04147338's enrollment target sits among peer trials
440 61st of 2000 higher than 1,939 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI